FDA pushes for all-electronic post-market ADR reporting
This article was originally published in Scrip
Executive Summary
The US FDA is proposing to amend its post-market safety reporting regulations for human drug and biological products to require that manufacturers with mandatory reporting requirements submit ADR reports in an electronic format.